arGEN-X Uses its Simple Antibody™ Platform to Identify Four 'Hotspots' on MET
as Targets for its Therapeutic Antibody Program
BREDA, The Netherlands and GHENT, Belgium, April 7, 2014
BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ --
New findings to be presented at the American Association for Cancer Research
arGEN-X, a clinical stage human therapeutic antibody company, will present
data on how its SIMPLE Antibody™ platform has identified four 'hotspots' on
the MET protein that are suitable for therapeutic antibody targeting. Encoded
by the oncogene c-Met, MET signalling is involved in cancer proliferation and
metastasis and is activated by hepatocyte growth factor (HGF) in multiple
The new findings, resulting from a collaboration between arGEN-X scientists
and the group of Professor Paolo Michieli at the Institute for Cancer Research
and Treatment (Turin, Italy), will be presented by Dr. Anna Hultberg of
arGEN-X on Tuesday 8 April in a Late-Breaking Mini-symposium at the American
Association for Cancer Research (AACR) annual meeting in San Diego, CA, USA.
Further details are given below.
Using its SIMPLE Antibody™ platform, arGEN-X selected 68 distinct antibodies
that competed with HGF for MET binding. From this panel, antibodies
recognizing four different regions or 'hotspots' for blockade of HGF-induced
signalling on the known extracellular domains of MET were identified. These
antibodies prevented metastatic spread in a triple-negative breast cancer
model following neo-adjuvant therapy, and in a mutated KRAS colon cancer model
as adjuvant therapy.
arGEN-X is targeting MET with ARGX-111, a SIMPLE Antibody™ based monoclonal
antibody with differentiated product features, currently in a Phase Ib
According to Prof. Hans de Haard, Chief Scientific Officer of arGEN-X: " MET
plays an important role in the signal transduction mechanisms responsible for
cancer cell spread. Based on our understanding of the importance of certain
MET epitopes in these mechanisms, we have created ARGX-111, a unique,
MET-specific antibody with several modes of therapeutic action ."
Details of the presentation are:
Four individually druggable MET hotspots mediate HGF-driven tumor progression
*Authors: Anna Hultberg, Cristina Basilico, Christophe Blanchetot, Natalie
De Jonge, Valérie Hanssens, Gitte De Boeck, Alessia Mira, Manuela
Cazzanti, Virginia Morello, Torsten Dreier, Michael Saunders, Hans De
Haard, and Paolo Michieli
*Abstract #LBB-330, Late-Breaking Mini-symposium: Novel Drug Targets,
Compounds, and Signatures of Response and Resistance
*Tuesday, 8 April, 4.35-4.50pm (Pacific time), Room 8, San Diego Conference
ARGX-111 is a human monoclonal antibody that blocks the known mechanisms of
action of the cancer target MET, the product of the c-Met oncogene. ARGX-111
was discovered using the SIMPLE Antibody™ platform and has been equipped with
NHance™ technology to optimize its pharmacokinetic half-life. Moreover, the
antibody has been produced as a de-fucosylated antibody using POTELLIGENT ^®
technology to boost Antibody Dependent Cellular Cytotoxicity (ADCC) and
potentiate immune system destruction of MET-positive tumor cells. With this
combination of unique attributes, ARGX-111 has demonstrated superior
therapeutic potential in both solid and hematological MET-positive
malignancies when compared to established biologic and small molecule
inhibitors of the target.
A first-in-man Phase Ib study (NCT02055066) is recruiting patients with
advanced MET over-expressing cancers that harbor circulating tumor cells
(CTCs), from which metastases are known to arise.
POTELLIGENT ^® technology is licensed by BioWa Inc., a wholly-owned subsidiary
of Kyowa Hakko Kirin Co. Ltd.
arGEN-X is a clinical stage human therapeutic antibody company that is rapidly
developing a product pipeline using its unique suite of antibody technologies.
arGEN-X is creating first and best in class antibody therapeutics with highly
differentiated target product profiles. Its therapeutic antibody programs,
focused on cancer and autoimmune indications, are designed to deliver tangible
benefits to patients with these diseases.
Contact: For further information, please contact: Tim Van Hauwermeiren, Chief
Executive Officer, T +32-(0)9-243-40-70; Debbie Allen, VP Business
Development, T +44-7974-979479, firstname.lastname@example.org. Mark Swallow/David Dible,
Citigate Dewe Rogerson, T +44-207-282-2949, arGEN-X@citigatedr.co.uk.
Press spacebar to pause and continue. Press esc to stop.